Kornimate/medical-research-clean huggingface dataset:
genomic endometrial expression in obesity

Conditions: Obesity and Embryo Implantation

Summary: determine if different genomic endometrial expression exists during embryo implantation in obese women in comparison with non obese women.


Eligibility criteria:
inclusion criteria: * group a: non obese oocyte donors (bmi: 18 - 29 kg. /m2)with proven fertility * group b: obese oocyte donors: (bmi: \>29 kg./m2)with proven fertility * group c: obese (bmi: \>29 kg./m2) infertile patients, exclusion criteria: * recurrent miscarriage
pulsatile cupping in low back pain

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to determine whether pulsatile cupping with a cupping device is effective in the treatment of patients with chronic low back pain compared to no cupping or to minimal cupping.


Eligibility criteria:
inclusion criteria: * male and female, 18-65 years * chronic low back pain (disease duration \> 3 months) * pain intensity on visual analogue scale at inclusion \> 40 mm (0-100 mm scale) * only pharmacological treatment with nsaid or no treatment in the last 4 weeks * undersigned informed consent form exclusion criteria: * use of anticoagulants (phenprocoumon, heparin) * coagulopathy * cupping in the last 6 weeks * other cam therapies in the last 12 weeks (e.g. acupuncture) * physical therapy in the last 12 weeks (e.g. massage, osteopathy) * participation in another study in the last 3 months * paracetamol allergy or intolerance * pathological neurological symptoms such as muscular paralysis or paraesthesia due to spinal disc herniation or other causes * known renal and / or hepatic diseases * intake of central nervous system-acting analgesics in the last 6 weeks * applying for early retirement due to low back pain * severe disease that does not allow participation * no undersigned informed consent form
study to compare the safety and pharmacokinetics of ckd-330 8/5mg with coadministration of the two separate drugs

Conditions: Hypertension

Summary: the purpose of this study is to compare the safety and pharmacokinetics of ckd-330 (fixed-dose combination of candesartan cilexetil 8 mg and amlodipine 5 mg) with coadministration of the two separate drugs in healthy male volunteers.


Eligibility criteria:
inclusion criteria: 1. healthy male volunteer in the age of 19-45 2. body weight ≥ 55 kg and in the range of calculated ibw ±20% 3. subject without a hereditary problems, chronic disease and morbid symptom 4. suitable clinical laboratory test values 5. subject who sign on an informed consent form willingly exclusion criteria: 1. clinically significant disease with hepatobiliary, nephrological, neurologic, respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system 2. gastrointestinal disease or gastrointestinal surgery 3. history of significant hypersensitivity reaction of amlodipine, candesartan, calcium channel blocker, angiotensin ii receptor blocker or other drugs 4. galactose intolerance 5. sitting systolic blood pressure ≥ 140 mmhg or\< 90 mmhg, sitting diastolic blood pressure ≥ 95 mmhg or \< 60 mmhg, pulse ≥ 100 beats per minute 6. aspartate aminotransferase, alanine aminotransferase, total bilirubin \> 2 x upper limit of normal range 7. serum creatinine \> upper limit of normal range 8. drug abuse 9. subject treated metabolizing enzyme inducers or inhibitors within 1 month 10. subject treated ethical the counter or herbal medicine within 2 weeks, over-the-counter or vitamin within 1 week 11. subject treated investigational product(include bioequivalence test) within 3 months 12. whole blood donation within 2 months, component blood donation or blood transfusion within 1 month 13. continuously taking alcohol \> 21 units/week 14. cigarette \> 10 cigarettes/day 15. subjects with planning of dental treatment or any surgery 16. another clinical condition in judgement of investigator

Keywords: hypertension healthy male volunteer candesartan, amlodipine
the use of angiotensin converting enzyme inhibitors and incident respiratory infections, are they harmful or protective?

Conditions: Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom

Summary: the study use uk based linked electronic health records from the clinical research datalink (caliber) of 5.6 million individuals to conduct a matched case-control study to investigate the incidence of influenza in individuals prescribed acei compared to those not prescribed acei.


Eligibility criteria:
inclusion criteria: * we identify individuals aged 18 years or older and registered in the current primary care practice for at least one year. exclusion criteria: * we exclude individuals with a prior history of influenza and viral pneumonia before study entry.
upurs trial for patient-centered management of symptomatic obstructing stones

Conditions: Ureteral Stone

Summary: a prospective, non-blinded, randomized controlled trial studying the management of symptomatic ureteral stones. this study will compare upfront ureteroscopy vs observation and delayed intervention for patients presenting to the emergency department with a symptomatic ureteral stone.

management of symptomatic ureteral stones is variable across the united states due to a lack of clear, patient-centered guidelines. for patients who do not meet criteria for emergent stenting, the decision to recommend upfront definitive treatment (ureteroscopy, eswl) or medical expulsion therapy is influenced by factors such as practice setting, insurance status, and day of the week. this has resulted in health disparities and delays in care that disproportionately affect vulnerable patient populations. for patients presenting to the emergency department with a symptomatic ureteral stone investigators will randomize into group a: upfront ureteroscopy or group b: delayed intervention and observation. both arms are considered standard of care for patients presenting with the above diagnosis.

Eligibility criteria:
inclusion criteria: * presenting to the emergency department (ed) * adult (\> 18 yo) * ≥5mm ureteral stone diagnosed on ct scan * presence of symptoms (pain, nausea, vomiting, hematuria) exclusion criteria: * strict indication for stent * stone burden not amenable to ureteroscopy (urs) * dirty urine analysis (ua) or positive urine culture (ucx) * transplant kidney * presence of conduit * comorbidities not optimized for surgery * strong preference for surgery or observation

Keywords: symptomatic ureteral stones
uterocervical angle and preterm labour

Conditions: Preterm Labor

Summary: to determine whether a novel ultrasonographic marker, uterocervical angle, correlates with risk of spontaneous preterm birth

the uterocervical angle is the triangular segment measured between the lower uterine segment and the cervical canal, yielding a measurable angle. the first ray was placed from the internal os to the external os. the calipers were placed where the anterior and posterior walls of the cervix touch the internal and external os along the endocervical canal. if the cervix was curved, the first ray was also drawn from the internal os to the external os as a straight line. a second ray was then drawn to delineate the lower uterine segment. this ray was traced up the anterior uterine segment to a distance allowed by the preloaded image. ideally, the second ray would reach 3cm up the lower uterine segment in order to establish an adequate measurement. the anterior angle in between the two rays was measured with a protractor. in the presence of funneling, the first ray was placed to measure the length of remaining cervix. the second caliper was placed from the innermost portion of measurable cervix and extended to the lower uterine segment. in the event that the lower uterine segment was found to be irregular, the second caliper was placed centrally along the segment. in the event of a retroverted uterus, the angle should be measured in a similar fashion with the first ray along the measurable cervix and the second ray traced along the lower uterine segment. unlike in an anteverted or axial positioned uterus, however, the posterior side of the angle closer to the intrauterine contents should then be measured.

Eligibility criteria:
inclusion criteria: * maternal age (18_40). * bmi (20_34). * singleton gestations between (18 - 28) weeks. * multiparity. * history of previous preterm deliveries or mid-trimesteric abortions. exclusion criteria: * loss of follow up. * preterm premature rupture of membranes(pprom). * placental abnormalities. * past history of cervical operations. * multifetal pregnancy. * polyhydramnios. * steroids intake . * medically or obstetric indicated pregnancy termination. * serious maternal or fetal problems. * cerclage during current pregnancy before the screening.

Keywords: uterocervical angle preterm birth
satisfaction and long-term anatomic efficacy study on patients who underwent a richter intervention in the obstetric and gynecology department of foch hospital since 2008

Conditions: Genital Prolapse

Summary: satisfaction and long-term anatomic efficacy will be assessed on patients who underwent a richter intervention in the obstetric and gynecology department of foch hospital since 2008.

satisfaction and long-term anatomic efficacy will be assessed on patients who underwent a richter intervention in the obstetric and gynecology department of foch hospital since 2008.

Eligibility criteria:
inclusion criteria: * patient who underwent a richter intervention between 01/01/2008 and 31/12/2017 in the gynecology department of foch hospital exclusion criteria: * none
safety and feasibility of immuno-oct

Conditions: Colon Carcinoma; Barrett Esophagus; Gastrointestinal Dysplasia

Summary: to improve detection of premalignant lesions in the gastrointestinal tract (the rectum and the esophagus) there is a need for better endoscopic visualization and the ability for targeted biopsies. the university medical center groningen (umcg) developed a fluorescent tracer by labelling the vegf-a-targeting humanized monoclonal antibody bevacizumab, currently used in anti-cancer therapy, with the fluorescent dye bevacizumab-800cw (irdye800cw). in several phase i studies and phase ii studies, either completed or currently running, in the umcg, the use of vegf-a-guided near-infrared (nir) fluorescence molecular endoscopy (fme) in combination with high-definition white light endoscopy (hd-wle) shows an improved detection rate of early premalignant lesions. in this study the safety and feasibility of a next generation imaging system will be tested. this system uses immune optical coherence tomography (immuno-oct) and near infrared fluorescence (nirf) with the targeted tracer (bevacizumab-800cw) for improvement of the detection of dysplastic lesions in barret's esophagus (be) and colorectal polyp detection. the system provides more depth information and can eventually be used without the guidance of the regular endoscopy system.


Eligibility criteria:
inclusion criteria: * indication for a therapeutic endoscopy procedure (emr or esd); * age ≥ 18; * written informed consent. exclusion criteria: * patients younger than 18 years old; * submucosal and invasive esophageal adenocarcinoma (eac) or colorectal carcinoma (crc); * radiation therapy for esophageal or colorectal cancer; * history of infusion reactions to bevacizumab or other monoclonal antibodies; * chemotherapy, immunotherapy or surgery 28 days before administration of the tracer; * non-adjustable hypertension; * medical or psychiatric conditions that compromise the patient's ability to give informed consent; * pregnancy or breastfeeding; a negative pregnancy test must be available for women of childbearing potential.

Keywords: optical coherence tomography
love together, parent together: a protocol for a pilot study of an intervention for interparental couples with young children

Conditions: Interparental Conflict; Marital Conflict; Marital Relationship; Internet-Based Intervention; Family Conflict

Summary: the covid-19 pandemic has created a population-level threat to social relationships that requires a population-level solution. among those who are particularly vulnerable to heightened conflict are interparental couples with young children, whose relationships may have already been under pressure prior to the pandemic. reduced couples' satisfaction has been reported since the start of the pandemic, with over one-third of romantic partners reporting heightened conflict due to covid-19. couples are likely to stay in disharmonious relationships during times of socioeconomic upheaval, with the potential for relationship problems to persist over time. this may have serious implications for the mental health of parents, parent-child relationships, and children's emotional and behavioural problems (ebps). such a pattern is a societal concern given the known associations between couples' relationship quality and a number of critical indicators of population health, such as intimate partner violence, physical health and all-cause mortality, and economic instability, particularly for women. the current study protocol is for a pilot randomized controlled trial (rct) of the love together parent together (l2p2) program-a brief, low-intensity, scalable relationship intervention for parents of young children. the two-arm (treatment vs. waitlist) pilot rct will assess the feasibility goals: continued relationship-building with established recruitment partners and outreach to additional recruitment partners to increase enrolment rates; recruitment of a diverse sample in terms of sociocultural identity factors, pandemic-related stress, and relationship distress; acceptability of randomization; outcome assessment schedule completion (for treatment and control groups), retention and adherence to the program; and program acceptability. additionally, the investigators will conduct a preliminary evaluation of treatment effects by examining group differences in couples-focused (i.e., couples' relationship, conflict-related negativity, interparental functioning) and family-focused outcomes (i.e., parent-child relations, parent mental health and child outcomes). a scalable couples-focused intervention is critically needed to circumvent the social consequences of the pandemic on young families.


Eligibility criteria:
inclusion criteria: * both participants endorse being in a relationship * both partners reside in the same house * there are one or more children under the age of 6 living at home * both participants are over age 18 years * both members of a couple agree to participate exclusion criteria: - no current plans or history of separation or divorce

Keywords: online intervention family systems randomized controlled trial writing intervention couples' relationships
wii balance board in dizziness

Conditions: Dizziness

Summary: patients with dizziness presently undergo physical therapy rehabilitation. our study will study whether wii balance board made by nintendo inc. will be helpful in patients with dizziness. they will undergo dizziness evaluation to quantify their dizziness.


Eligibility criteria:
inclusion criteria: * abnormal posturography exam exclusion criteria: * pregnant women and children
visilizumab for moderate to severe inflammatory, nonstricturing, nonpenetrating crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat moderate to severe inflammatory, nonstricturing, nonpenetrating crohn's disease. the research is being conducted at up to 5 clinical research sites in the us and europe and is open to both men and women ages 18 to 70 years old. participants in the study will have a number of visits to a research site up to 17 months. all study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work. visilizumab is a humanized antibody (antibodies are proteins that are normally made by the immune system to help defend the body from infections and other foreign substances) that is directed against t cells. visilizumab selectively attacks problematic t cells and, in doing so, it may prevent them from causing inflammation. visilizumab has also been observed to have a suppressive effect on the body's immune system (system in the body that reacts to foreign or occasionally one's own proteins).

pdl biopharma, inc. was formerly known as protein design labs, inc.

Eligibility criteria:
inclusion criteria: * 18-70 years old * diagnosis of moderate-to-severe inflammatory, nonstricturing, nonpenetrating crohn's disease, defined as crohn's disease activity index greater than or equal to 250, c-reactive protein greater than or equal to upper limit of normal, and endoscopic evidence of moderate-to-severe active inflammatory disease * test negative for clostridium difficile within 3 weeks * signed informed consent, including permission to use protected health information exclusion criteria: * history of lymphoproliferative disorder or prior malignancy within 5 years or current malignancy * pregnant or nursing * hiv, hepatitis b or hepatitis c infection * presence of obstructive symptoms, confirmed by endoscopy * serious infections within 12 months * active infections that require antibiotic therapy * started or changed dose of sulfasalazine, 5-aminosalicylic acid; or antibiotics, probiotics, or topical therapies for crohn's within 2 weeks * serious infections that required iv antibiotic therapy or hospitalization within 8 weeks * increase dose of corticosteroid medication within 2 weeks * received a live vaccine within 6 weeks * received any monoclonal antibodies or investigational agents within 3 months * received cyclosporine or tacrolimus (fk506) within 4 weeks * dose change or discontinuation from 6-mercaptopurine, azathioprine, or methotrexate within 4 weeks * significant organ dysfunction * likely to require surgery in the next 6 months * history of lymphoproliferative disorder * history of tuberculosis or mycobacteria infection or positive chest x-ray * history of thrombophlebitis or pulmonary embolus * history of immune deficiency or autoimmune disorders other than crohn's * history of subtherapeutic blood levels of anticonvulsive medications within 1 week
the volume effect of hydrodissection for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the investigators investigated the volume effect of hydrodissection for injection therapies in patients with carpal tunnel syndrome. the investigators evaluated participants by shear wave ultrasound elastography and artificial intelligence imaging analysis

the investigators investigated the volume effect of hydrodissection for injection therapies in patients with carpal tunnel syndrome. the investigators evaluated participants by shear wave ultrasound elastography and artificial intelligence imaging analysis

Eligibility criteria:
inclusion criteria: * age 20-80 * electrophysiological diagnosis of carpal tunnel syndrome * at least one of the following two: 1. tenderness or numbness over median nerve innervated dermatome over 2 months 2. phalen test or tinel sign or flick sign positive exclusion criteria: * history of wrist surgery * wrist trauma in recent two years * received wrist injection in recent three months * history of brachial plexopathy, cervical radiculopathy or thoracic outlet syndrome * history of dm, thyroid disorder or autoimmune disease * unable to cooperate with interview, examination or injection
caffeic acid tablets as a second-line therapy for itp

Conditions: Immune Thrombocytopenia

Summary: the investigators are undertaking a multicentre, randomised controlled trial of 120 adults with newly diagnosed itp from 5 medical centers in china. part of the participants are randomly selected to receive caffeic acid tablets combining dexamethasone and the other part are selected to receive high-dose dexamethasone treatment. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study.

all participants' platelet count will be monitored weekly. response will be evaluated after 3, 6 and 12 months after treatment. if the participant did not get complete response or response after 3 months, he would quit the trail.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria for immune thrombocytopenia 2. untreated hospitalized patients, may be male or female, between the ages of 18 \~ 80 years 3. to show a platelet count \<30 \* 10\^9/l, and with bleeding manifestations 4. willing and able to sign written informed consent exclusion criteria: 1. received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit 2. received second-line itp-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit 3. received high-dose steroids or ivig in the 3 weeks prior to the start of the study 4. current hiv infection or hepatitis b virus or hepatitis c virus infections 5. severe medical condition (lung, hepatic or renal disorder) other than chronic itp. unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 6. female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period 7. have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test 8. patients who are deemed unsuitable for the study by the investigator
covid-19 at the regional medical center metz-thionville: a descriptive study

Conditions: COVID

Summary: france and especially the region "grand est" have been damaged by the covid-19 pandemic. this pandemic resulted in a reorganization of the hospitalization sectors. in order to better understand the disease, the investigators wish to carry out a descriptive analysis of hospitalized patient data. this study would notably allow us to identify some prognostic factors. the main objective of this study is to identify individual factors that are associated with a poor prognosis (with icu admission or death).


Eligibility criteria:
inclusion criteria: * patient hospitalized in covid unit at the regional hospital center metz-thionville during the covid 19 pandemic * pcr positive or covid confirmed with clinical evidence and ct scan exclusion criteria: * patients not willing to participate via using their medical files * patient transferred after a brief stay in another hospital
combining lidocaine and ropivacaine for an infraclavicular brachial plexus nerve block

Conditions: Nerve Block; Anesthesia, Local; Forearm Fracture; Surgery; Brachial Plexus Block

Summary: the aim of the study is to investigate how the combination of ropivacaine (a slow onset, long duration local anesthetic) with lidocaine (a rapid onset, shorter duration local anesthetic) affects the onset and duration of a lateral infraclavicular plexus brachialis (lic) block in patients undergoing non-acute hand surgery.


Eligibility criteria:
patient who have given written informed consent to participate in the study, after having understood it inclusion criteria: * scheduled for non-acute hand surgery in regional anesthesia * scheduled for surgery on one of the following: 1) antebrachium fractures or 2) arthroplasty of a thumb base joint or 3) alloplasty of a thumb base joint exclusion criteria: * bmi \> 40 kg/m2 * weight \< 60 kg * age \< 18 years * asa physical status classification system grade \> 3 * allergy to experimental drugs * patients who cannot cooperate with the examinations or treatment * patients who do not understand or speak danish * patients with peripheral or central neurological disease or nerve damage with neurological effect on the upper extremity, where surgery is required

Keywords: anesthetics, local lidocaine ropivacaine